INCY
INCYTE CORP
NASDAQ · Healthcare · Biotechnology · US
$125.31
−1.81%Next report
Analyst consensus
- Next report date
- Oct 27, 2026
- EPS estimate
- -$3.31
- Revenue estimate
- $1.5B
Latest reported
- Last report date
- Jul 28, 2026
- EPS actual
- $3.09
- EPS estimate
- $2.15
- Revenue actual
- $1.7B
- Revenue estimate
- $1.5B
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +31.0%
- Revenue beats (12Q)
- 6
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $130
- PT range
- $104 – $155
- Analysts
- 13
7 Buy6 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Jul 28, 2026 | $2.15 | $3.09 | Beat 43.72% | $1.7B |
| Apr 28, 2026 | $1.38 | $1.81 | Beat 31.16% | $1.3B |
| Oct 28, 2025 | $1.66 | $2.26 | Beat 36.14% | $1.4B |
| Jul 29, 2025 | $1.39 | $1.57 | Beat 12.95% | $1.2B |
| Apr 30, 2024 | $0.83 | $0.64 | Miss -23.17% | $880.9M |
| Feb 13, 2024 | $1.15 | $1.06 | Miss -8.15% | $1.0B |
| Oct 31, 2023 | $1.08 | $1.10 | Beat 1.95% | $919.0M |
| Aug 1, 2023 | $0.83 | $0.99 | Beat 19.28% | $954.6M |
| May 2, 2023 | $0.85 | $0.37 | Miss -56.47% | $808.7M |
| Feb 7, 2023 | $0.59 | $0.62 | Beat 5.08% | $926.7M |
| Nov 1, 2022 | $0.72 | $0.60 | Miss -16.67% | $823.3M |
| Aug 2, 2022 | $0.79 | $1.01 | Beat 27.85% | $911.4M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 27, 2026